argenx NV ADR (ARGX)vsBeam Therapeutics Inc (BEAM)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
BEAM
Beam Therapeutics Inc
$28.78
+15.58%
HEALTHCARE · Cap: $2.42B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 3691% more annual revenue ($5.92B vs $156.03M). ARGX leads profitability with a 31.7% profit margin vs -55.4%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
BEAM
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Intrinsic value data unavailable for BEAM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
0.0% earnings growth
ROE of -5.8% — below average capital efficiency
Revenue declined 94.2%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : BEAM
The strongest argument for BEAM centers on Debt/Equity, Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : BEAM
The primary concerns for BEAM are EPS Growth, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ARGX profiles as a growth stock while BEAM is a turnaround play — different risk/reward profiles.
BEAM carries more volatility with a beta of 2.20 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 25/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Beam Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?